Despite the Use of the Combination of G-CSF and Plerixafor for Stem Cell Mobilization, One Third of the Patients with Lymphoma Were Still 'Poor Mobilizer' Using the Criteria Recently Proposed by GITMO (< 2.0 X 106 CD 34 + Cells Per Kg in ≤ 3 Apheresis)

Autor:	Antonio M. Jimenez, Kent W. Christopherson, Henry C. Fung, Elizabeth Rich, John Maciejewski, Jennifer Tornatta, Bruce C. McLeod, Reem Karmali, Stephanie A. Gregory, Sunita Nathan
Rok vydání:	2012
Předmět:	Oncology Transplantation medicine.medical_specialty business.industry Stem cell mobilization Plerixafor Hematology medicine.disease Lymphoma Apheresis Internal medicine Immunology Medicine business medicine.drug
Zdroj:	Biology of Blood and Marrow Transplantation. 18:S263
ISSN:	1083-8791
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65ecb8122bc3bbb610bb1a0adc403e85 https://doi.org/10.1016/j.bbmt.2011.12.175 Zobrazit plný text záznamu Full Text from ScienceDirect